Biocon launches anti-CD-6 psoriasis biologic in India

India's largest biotechnology firm, Biocon, has launched its first-in-class anti-CD6 monoclonal antibody, itolizumab (marketed as Alzumab), for chronic plaque psoriasis, on the domestic market.

India's largest biotechnology firm, Biocon, has launched its first-in-class anti-CD6 monoclonal antibody, itolizumab (marketed as Alzumab), for chronic plaque psoriasis, on the domestic market.

Priced at INR7,950 ($130.5) per vial, the product is about 50% cheaper than existing competing therapies, such as Johnson &...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category